Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « administration »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
administered < administration < administrations  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 24.
[0-20] [0 - 20][0 - 24][20-23][20-40]
Ident.Authors (with country if any)Title
000005 (2020) Tadeusz Płusa[Options for controlling new Corona virus infection - 2019-nCoV].
000008 (2020) J. Prinz [Allemagne] ; Y. D'Hargues [Allemagne] ; P. Gödel [Allemagne] ; A. Shimabukuro-Vornhagen [Allemagne] ; M. Kochanek [Allemagne] ; B. Böll [Allemagne][CARs, CRS and neurotoxicity: severe complications after administration of immunotherapy : Essentials for intensivists].
000034 (2020) Angelika Batta ; Bhupinder Singh Kalra ; Raj KhirasariaTrends in FDA drug approvals over last 2 decades: An observational study
000055 (2020) Pan Luo [République populaire de Chine] ; Yi Liu [République populaire de Chine] ; Lin Qiu [République populaire de Chine] ; Xiulan Liu [République populaire de Chine] ; Dong Liu [République populaire de Chine] ; Juan Li [République populaire de Chine]Tocilizumab treatment in COVID-19: A single center experience.
000059 (2020) Banafsheh Mosharmovahed [Iran] ; Yousef Fatahi [Iran] ; Bahareh Mohebbi [Iran] ; Sohrab Ali Ghorbanian [Iran] ; Sara Assadiasl [Iran]Tocilizumab in transplantation.
000090 (2020) Muneyoshi Futami [Japon] ; Keisuke Suzuki [Japon] ; Satomi Kato [Japon] ; Saori Ohmae [Japon] ; Yoshio Tahara [Japon] ; Masanori Nojima [Japon] ; Yoichi Imai [Japon] ; Takayuki Mimura [Japon] ; Yoshihiro Watanabe [Japon] ; Arinobu Tojo [Japon]The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells.
000144 (2020) Wolfgang F. Richter [Suisse] ; Hans-Peter Grimm [Suisse] ; Marie-Hélène Gouy [Suisse] ; Susi S Gaard [Danemark] ; Caroline Kreuzer [Suisse] ; Uwe Wessels [Allemagne] ; Dragomir Draganov [Suisse] ; Chris Muenzer [Suisse] ; Tonio Hoche [Suisse]Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans.
000199 (2020) Tarek Mohamed Abd El-Aziz [États-Unis, Égypte] ; James D. Stockand [États-Unis]Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
000208 (2020) Natalia Maximova [Italie] ; Alessandra Maestro [Italie] ; Davide Zanon [Italie] ; Annalisa Marcuzzi [Italie]Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
000221 (2020) Yao-Chung Liu [Taïwan] ; Ting-An Lin [Taïwan] ; Hao-Yuan Wang [Taïwan] ; Po-Shen Ko [Taïwan] ; Chia-Jen Liu [Taïwan] ; Liang-Tsai Hsiao [Taïwan] ; Sheng-Hsuan Chien [Taïwan] ; Jyh-Pyng Gau [Taïwan]Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report
000350 (2020) Anna-Sophia Kattner ; Ernst Holler ; Barbara Holler ; Sebastian Klobuch ; Daniela Weber ; Danilo Martinovic ; Matthias Edinger ; Wolfgang Herr ; Daniel WolffIL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis
000367 (2020) Charlotte Hua [France] ; Frank Buttgereit [Allemagne] ; Bernard Combe [France]Glucocorticoids in rheumatoid arthritis: current status and future studies
000386 (2020) Matthew Mankarious [Royaume-Uni] ; Nick C. Matthews [Royaume-Uni] ; John A. Snowden [Royaume-Uni] ; Arun Alfred [Royaume-Uni]Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD)
000434 (2020) Rahime Koç [Turquie] ; Hafize Emine Sönmez [Turquie] ; Mustafa Çakan [Turquie] ; Erife Gül Karada [Turquie] ; Ay E Tanatar [Turquie] ; Figen Çakmak [Turquie] ; Nuray Aktay Ayaz [Turquie]Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center.
000441 (2020) Ruei-Min Lu [Taïwan] ; Yu-Chyi Hwang [Taïwan] ; I-Ju Liu [Taïwan] ; Chi-Chiu Lee [Taïwan] ; Han-Zen Tsai [Taïwan] ; Hsin-Jung Li [Taïwan] ; Han-Chung Wu [Taïwan]Development of therapeutic antibodies for the treatment of diseases
000454 (2020) He Huang [République populaire de Chine] ; Heng-Wei Wu [République populaire de Chine] ; Yong-Xian Hu [République populaire de Chine]Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma
000456 (2020) Francesco Fontana [Italie] ; Gaetano Alfano [Italie] ; Giacomo Mori [Italie] ; Alessio Amurri [Italie] ; Tei Lorenzo [Italie] ; Marco Ballestri [Italie] ; Marco Leonelli [Italie] ; Francesca Facchini [Italie] ; Francesca Damiano [Italie] ; Riccardo Magistroni [Italie] ; Gianni Cappelli [Italie]Covid-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine.
000512 (2020) Veronika Bachanova [États-Unis] ; Michael R. Bishop [États-Unis] ; Parastoo Dahi [États-Unis] ; Bhagirathbhai Dholaria [États-Unis] ; Stephan A. Grupp [États-Unis] ; Brandon Hayes-Lattin [États-Unis] ; Murali Janakiram [États-Unis] ; Richard T. Maziarz [États-Unis] ; Joseph P. Mcguirk [États-Unis] ; Loretta J. Nastoupil [États-Unis] ; Olalekan O. Oluwole [États-Unis] ; Miguel-Angel Perales [États-Unis] ; David L. Porter [États-Unis] ; Peter A. Riedell [États-Unis]Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
000560 (2020) Ranjit Nair [États-Unis] ; Jason Westin [États-Unis]CAR T-Cells.
000573 (2020) Izabela Szczygielska ; El Bieta Hernik ; Agnieszka Gazda ; Beata Kołodziejczyk ; Piotr GietkaAssessment of anti-HBs antibody concentration in children with juvenile idiopathic arthritis treated with biological drugs, vaccinated against viral type B hepatitis in infancy
000585 (2020) Zakir Khan [Pakistan] ; Yusuf Karata [Turquie] ; Hazir RahmanAnti COVID-19 Drugs: Need for More Clinical Evidence and Global Action

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "administration" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "administration" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    administration
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021